{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:07Z","timestamp":1787020987264,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Insomnia is a common condition experienced by many individuals with excessive alcohol use and alcohol use disorder, and the serotonin antagonist and reuptake inhibitor trazodone has emerged as a mainstay of treatment for insomnia in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>However, an underappreciated literature has demonstrated potential for an increase in alcohol use while persons with alcohol use disorder are taking trazodone for sleep challenges. Additionally, multiple trials have identified trazodone\u2019s metabolite meta-Chlorophenylpiperazine as a pharmaceutical inducer of increased alcohol craving and use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Increased awareness in the potential of worsening drinking behaviour with trazodone accompanied by the preferential use of safer alternative treatment strategies can likely improve outcomes for patients with heavy drinking and alcohol use disorder.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00552-3","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T22:51:07Z","timestamp":1742856667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rethinking trazodone for insomnia in alcohol use disorder"],"prefix":"10.1186","volume":"20","author":[{"given":"Jeffrey","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"552_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.alcohol.2022.11.002","volume":"108","author":"I Bolstad","year":"2023","unstructured":"Bolstad I, Toft H, Lien L, Moe JS, Rolland B, Bramness JG. Longitudinal determinants of insomnia among patients with alcohol use disorder. Alcohol. 2023;108:10\u201320.","journal-title":"Alcohol"},{"key":"552_CR2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3389\/fphar.2019.01164","volume":"10","author":"F Panin","year":"2019","unstructured":"Panin F, Peana AT. Sleep and the pharmacotherapy of alcohol use disorder: unfortunate bedfellows. A systematic review with Meta-Analysis. Front Pharmacol. 2019;10:1164.","journal-title":"Front Pharmacol"},{"key":"552_CR3","doi-asserted-by":"crossref","unstructured":"Chaudhary NS, Kampman KM, Kranzler HR, Grandner MA, Debbarma S, Chakravorty S. Insomnia in alcohol dependent subjects is associated with greater psychosocial problem severity. 2015(1873\u20136327 (Electronic)).","DOI":"10.1016\/j.addbeh.2015.06.021"},{"key":"552_CR4","doi-asserted-by":"crossref","unstructured":"Perney P, Rigole H, Fau - Mason B, Mason B, Fau - Dematteis M, Dematteis M, Fau - Lehert P, Lehert P. Measuring sleep disturbances in patients with alcohol use disorders: a short questionnaire suitable for routine practice. 2015(1935\u20133227 (Electronic)).","DOI":"10.1097\/ADM.0000000000000063"},{"key":"552_CR5","unstructured":"Substance Abuse and Mental Health Services Administration. Treat Sleep Probl People Recovery Subst Use Disorders. 2014;8(2)."},{"issue":"6","key":"552_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/fcp.12678","volume":"35","author":"E Lopez","year":"2021","unstructured":"Lopez E, Jeanne G, Lefort LH, Autissier C, Picot MC, Peyri\u00e8re H, et al. Characterization of benzodiazepine misuse and comorbidities in patients with alcohol use disorder. Fundam Clin Pharmacol. 2021;35(6):1133\u201340.","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"552_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1300\/J069v22n02_08","volume":"22","author":"PD Friedmann","year":"2003","unstructured":"Friedmann PD, Herman DS, Freedman S, Lemon SC, Ramsey S, Stein MD. Treatment of sleep disturbance in alcohol recovery: a National survey of addiction medicine physicians. J Addict Dis. 2003;22(2):91\u2013103.","journal-title":"J Addict Dis"},{"key":"552_CR8","doi-asserted-by":"crossref","unstructured":"Pelayo R, Bertisch SM, Morin CM, Winkelman JW, Zee PC, Krystal AD. Should Trazodone be First-Line therapy for insomnia?? A clinical suitability appraisal. J Clin Med. 2023;12(8).","DOI":"10.3390\/jcm12082933"},{"issue":"1","key":"552_CR9","doi-asserted-by":"publisher","first-page":"14453","DOI":"10.1038\/s41598-022-18776-7","volume":"12","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Lv T, Wu J, Lyu Y. Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis. Sci Rep. 2022;12(1):14453.","journal-title":"Sci Rep"},{"issue":"5","key":"552_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/alcalc\/agr073","volume":"46","author":"BP Kolla","year":"2011","unstructured":"Kolla BP, Mansukhani MP, Schneekloth T. Pharmacological treatment of insomnia in alcohol recovery: a systematic review. Alcohol Alcohol. 2011;46(5):578\u201385.","journal-title":"Alcohol Alcohol"},{"key":"552_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jad.2016.03.024","volume":"198","author":"M Zimmerman","year":"2016","unstructured":"Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Variability in the substance use disorder exclusion criterion in antidepressant efficacy trials. J Affect Disord. 2016;198:39\u201342.","journal-title":"J Affect Disord"},{"issue":"9","key":"552_CR12","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/j.1530-0277.2008.00742.x","volume":"32","author":"PD Friedmann","year":"2008","unstructured":"Friedmann PD, Rose JS, Swift R, Stout RL, Millman RP, Stein MD. Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2008;32(9):1652\u201360.","journal-title":"Alcohol Clin Exp Res"},{"key":"552_CR13","doi-asserted-by":"crossref","unstructured":"Dundon W. Lynch Kg Fau - Pettinati HM, Pettinati Hm Fau - Lipkin C, Lipkin C. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. 2004(0145\u20136008 (Print)).","DOI":"10.1097\/01.ALC.0000130974.50563.04"},{"key":"552_CR14","doi-asserted-by":"crossref","unstructured":"Wetzel H, Szegedi A, Fau - Scheurich A, Scheurich A, Fau - L\u00f6rch B, L\u00f6rch B, Fau - Singer P, Singer P. Fau - Schl\u00e4fke D, Schl\u00e4fke D Fau - Sittinger H, Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. 2004(0160\u20136689 (Print)).","DOI":"10.4088\/JCP.v65n1017"},{"issue":"3","key":"552_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/ADM.0b013e318165cb56","volume":"2","author":"EP Monnelly","year":"2008","unstructured":"Monnelly EP, LoCastro JS, Gagnon D, Young M, Fiore LD. Quetiapine versus Trazodone in reducing rehospitalization for alcohol dependence: A large Data-Base study. J Addict Med. 2008;2(3):128\u201334.","journal-title":"J Addict Med"},{"issue":"6","key":"552_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1521-0391.2011.00172.x","volume":"20","author":"BP Kolla","year":"2011","unstructured":"Kolla BP, Schneekloth TD, Biernacka JM, Frye MA, Mansukhani MP, Hall-Flavin DK, et al. Trazodone and alcohol relapse: a retrospective study following residential treatment. Am J Addict. 2011;20(6):525\u20139.","journal-title":"Am J Addict"},{"issue":"4","key":"552_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/archpsyc.1991.01810280099018","volume":"48","author":"C Benkelfat","year":"1991","unstructured":"Benkelfat C, Murphy DL, Hill JL, George DT, Nutt D, Linnoila M. Ethanollike properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry. 1991;48(4):383.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"552_CR18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/archpsyc.1994.03950110058008","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS. Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry. 1994;51(11):898\u2013911.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"552_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1530-0277.1997.tb03753.x","volume":"21","author":"L Buydens-Branchey","year":"2006","unstructured":"Buydens-Branchey L, Branchey M, Fergeson P, Hudson J, McKernin C. Hormonal, psychological, and alcohol craving changes after m\u2010Chlorophenylpiperazine administration in alcoholics. Alcoholism: Clin Experimental Res. 2006;21(2):220\u20137.","journal-title":"Alcoholism: Clin Experimental Res"},{"issue":"6","key":"552_CR20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/npp.2010.253","volume":"36","author":"JC Umhau","year":"2011","unstructured":"Umhau JC, Schwandt ML, Usala J, Geyer C, Singley E, George DT, et al. Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Neuropsychopharmacology. 2011;36(6):1178\u201386.","journal-title":"Neuropsychopharmacology"},{"key":"552_CR21","doi-asserted-by":"crossref","unstructured":"Wood E, Rehm J. Addressing the risks of antidepressants among people with alcohol use disorders. Can Med Assoc J. 2024.","DOI":"10.1503\/cmaj.150095-l"},{"issue":"4","key":"552_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1037\/0022-006X.70.4.887","volume":"70","author":"R Niaura","year":"2002","unstructured":"Niaura R, Spring B, Borrelli B, Hedeker D, Goldstein MG, Keuthen N, et al. Multicenter trial of Fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol. 2002;70(4):887\u201396.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"552_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1037\/0022-006X.75.1.85","volume":"75","author":"B Spring","year":"2007","unstructured":"Spring B, Doran N, Pagoto S, McChargue D, Cook JW, Bailey K, et al. Fluoxetine, smoking, and history of major depression: A randomized controlled trial. J Consult Clin Psychol. 2007;75(1):85\u201394.","journal-title":"J Consult Clin Psychol"},{"issue":"3","key":"552_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00004714-199506000-00004","volume":"15","author":"J Grabowski","year":"1995","unstructured":"Grabowski J, Rhoades H, Elk R, Schmitz J, Davis C, Creson D, et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol. 1995;15(3):163\u201374.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"552_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0376-8716(00)00208-8","volume":"63","author":"JM Schmitz","year":"2001","unstructured":"Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend. 2001;63(3):207\u201314.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"552_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2006.03.005","volume":"85","author":"S Shoptaw","year":"2006","unstructured":"Shoptaw S, Huber A, Peck J, Yang X, Liu J, Jeff D, et al. Randomized, placebo-controlled trial of Sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85(1):12\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"2\u20133","key":"552_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.drugalcdep.2011.04.015","volume":"118","author":"T Zorick","year":"2011","unstructured":"Zorick T, Sugar CA, Hellemann G, Shoptaw S, London ED. Poor response to Sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug Alcohol Depend. 2011;118(2\u20133):500\u20133.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"552_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/add.12108","volume":"108","author":"FR Levin","year":"2013","unstructured":"Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, et al. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction. 2013;108(6):1084\u201394.","journal-title":"Addiction"},{"issue":"1","key":"552_CR29","first-page":"Cd007505","volume":"1","author":"JC Ipser","year":"2015","unstructured":"Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ. Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev. 2015;1(1):Cd007505.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"552_CR30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/0706743720915420","volume":"65","author":"PRA Stokes","year":"2020","unstructured":"Stokes PRA, Jokinen T, Amawi S, Qureshi M, Husain MI, Yatham LN, et al. Pharmacological treatment of mood disorders and comorbid addictions: A systematic review and Meta-Analysis: traitement pharmacologique des troubles de l\u2019humeur et des d\u00e9pendances comorbides: Une revue syst\u00e9matique et Une M\u00e9ta-Analyse. Can J Psychiatry. 2020;65(11):749\u201369.","journal-title":"Can J Psychiatry"},{"key":"552_CR31","doi-asserted-by":"crossref","unstructured":"Garcia CC, Richards DK, Tuchman FR, Hallgren KA, Kranzler HR, Aubin HJ et al. Reductions in World Health Organization risk drinking level are associated with improvements in sleep problems among individuals with alcohol use disorder. Alcohol and alcoholism (Oxford, Oxfordshire). 2024;59(3).","DOI":"10.1093\/alcalc\/agae022"},{"issue":"5","key":"552_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1521-0391.2011.00152.x","volume":"20","author":"KJ Brower","year":"2011","unstructured":"Brower KJ, Krentzman A, Robinson EA. Persistent insomnia, abstinence, and moderate drinking in alcohol-dependent individuals. Am J Addict. 2011;20(5):435\u201340.","journal-title":"Am J Addict"},{"issue":"1","key":"552_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/13543784.2018.1417383","volume":"27","author":"BJ Mason","year":"2018","unstructured":"Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018;27(1):113\u201324.","journal-title":"Expert Opin Investig Drugs"},{"key":"552_CR34","first-page":"E1364","volume-title":"Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder","author":"E Wood","year":"2023","unstructured":"Wood E, Bright J, Hsu K, Goel N, Ross JWG, Hanson A, et al. Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder. Volume 195. CMAJ: Canadian Medical Association journal\u2009=\u2009journal de l\u2019Association medicale canadienne; 2023. pp. E1364\u201379. 40."},{"issue":"3","key":"552_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/14656566.2019.1705279","volume":"21","author":"PA Geoffroy","year":"2020","unstructured":"Geoffroy PA, Lejoyeux M, Rolland B. Management of insomnia in alcohol use disorder. Expert Opin Pharmacother. 2020;21(3):297\u2013306.","journal-title":"Expert Opin Pharmacother"},{"key":"552_CR36","doi-asserted-by":"crossref","unstructured":"Chakravorty SA-O, Morales KH, Arnedt JT, Perlis ML, Oslin DW, Findley JC et al. Cognitive Behavioral Therapy for Insomnia in Alcohol-Dependent Veterans: A Randomized, Controlled Pilot Study. 2019(1530\u2013\u20090277 (Electronic)).","DOI":"10.1111\/acer.14030"},{"issue":"1","key":"552_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13012-022-01247-y","volume":"17","author":"S Ingvarsson","year":"2022","unstructured":"Ingvarsson S, Hasson H, von Thiele Schwarz U, Nilsen P, Powell BJ, Lindberg C, et al. Strategies for de-implementation of low-value care\u2014a scoping review. Implement Sci. 2022;17(1):73.","journal-title":"Implement Sci"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00552-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T22:01:22Z","timestamp":1742940082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00552-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00552-3","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Evan Wood is a physician who works for Vancouver Coastal Health in the area of withdrawal management and undertakes work in the area of occupational addiction medicine. Dr. Wood is also a professor of medicine based at the University of British Columbia (UBC), a position supported by a Canadian Institutes of Health Research (CIHR) Tier 1 Canada Research Chair, and has received salary support from an R01 from the US National Institute on Drug Abuse, paid to UBC. Dr. Wood\u2019s research lab is further supported by CIHR grants to the Canadian Research Initiative in Substance Misuse. Dr. Wood has also undertaken consulting work in legal matters related to substance use disorders and for a mental health company called Numinus Wellness, where Dr. Wood is former chief medical officer; Dr. Wood has also received compensation in the form of equity in Numinus. Dr. Wood reports receiving honoraria for non-industry related academic lectures and conference presentations. Dr. Wood has also received payment for expert reports and expert testimony in legal matters pertaining to substance use disorder, including from the Canadian Medical Protective Association and from trade unions representing workers with possible substance use disorder. Dr. Wood has received travel support from the CIHR.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}